top of page


Lancet Neurology publishes landmark paper of a potential therapy for ALS developed in collaboration with UCSD and Isis Pharmaceutical Co: "An Antisense Oligonucleotide against SOD1 Delivered Intrathecally for Patients with SOD1-Familial Amyotrophic Lateral Sclerosis: a phase 1, randomized, first-in man study."

Dr. Smith counseled an ALS patient in Guatemala using Skype.

Dr. Smith spoke in Houston on Monday, October 22nd 2012 at the invitation of Dr. Stan Appel, Director of the CHAO brain center at Methodist Hospital.

bottom of page